John F. DiPersio, MD, PhD

Researchers have developed a genetically modified form of the immune-stimulating protein interleukin-7 that significantly enhanced chimeric antigen receptor T-cell therapy activity in preclinical testing.

A myeloablative fractionated busulfan regimen with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis appeared feasible for older patients with hematologic malignancies, according to results of a single-arm phase 2 study presented at TCT | Transplantation & Cellular Therapy Meetings.

Researchers at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have used gene editing technology known as CRISPR to engineer human T cells to attack certain cancers.